Navigation Links
McMaster study contradicts reports of problems with blood-thinner
Date:8/29/2010

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

After researchers from the United States, France and Germany reported clopidogrel is less effective in some patients, the Food and Drug Administration (FDA) in the United States issued a black box warning to physicians on the drug's package insert.

"(Our findings) add a further layer of complexity to the FDA 'black box' warning and show that reported genetic variants have no effect in certain patient populations," said Dr. Guillaume Par, lead researcher and assistant professor of pathology and molecular medicine at the Michael G. DeGroote School of Medicine.

Clopidogrel is the world's second best-selling prescription drug with global sales of more than $6 billion annually. It is used in 110 countries by millions of people to reduce the risk of heart attack and stroke.

Following the FDA's warning, clopidogrel became the focus of on-going debates within cardiology circles. Some American cardiologists initially called the FDA's actions irresponsible. Others complained they were left without any appropriate direction on how to manage their patients.

About 20 per cent of the population carry the loss-of-function version of the gene involved in the clopidogrel controversy.

To assess the influence genetics might have on patients prescribed clopidogrel, Par and colleagues from McMaster University conducted a genetic sub-study of 6,000 participants from two major clinical trials (CURE and ACTIVE). The CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events) trial of 12,562 patients with acute coronary syndrome in 28 countries found clopidogrel significantly reduces the risk of heart attack stroke and dying. The ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for the Prevention of Vascular Events) trial of 7,554 patients with atrial fibrillation in 30 countries found clopidogrel added to Aspirin significantly reduced the risk of cardiovascular events, and particularly stroke. Both trials were supported by Sanofi-Aventis and Bristol-Myers Squibb.

"We found the previously reported genetic variants had no effect at all (for patients) in either the CURE or ACTIVE trials," said Par. He will present these findings at the European Cardiovascular Society Congress meeting in Stockholm, Sweden, on August 29. The study will also be simultaneously published online in the New England Journal of Medicine.

Par said the positive results from McMaster's genetic sub-study come from studying different patient populations. "Also, our study design was a bit stronger from an epidemiology point of view."

Beyond clopidogrel, he said there is a broader message of the need for cautiousness as genetics becomes more and more integrated into patient care.


'/>"/>

Contact: Laura Thompson
lthomp@mcmaster.ca
905-525-9140
McMaster University
Source:Eurekalert

Related medicine news :

1. McMaster researcher leads development of promising drug for inflammation
2. Vaccine has cut child cases of bacterial pneumonia, says study
3. Even Before Recession, 14 Million Kids Underinsured: Study
4. Penn study sheds light on how the brain shifts between sleep/awake states under anesthesia
5. Study Links Gene to Serious Eye Disease
6. Study Suggests Statins Could Help Some With Normal Cholesterol
7. Heart Risks the Same With 2 Diabetes Drugs: Study
8. Mayo researchers develop new laboratory cell lines to study treatment for ATC
9. Herpes Drugs Wont Raise Birth Defect Risk, Study Finds
10. Mumps vaccine coverage should be improved, study finds
11. Study Suggests Link Between Diet Sodas, Preterm Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... PITTSBURGH, PA (PRWEB) , ... September 22, 2017 ... ... as soon as possible, and they often saves lives. However, if one isn’t ... order to widen the availability of defibrillation, I came up with this idea," ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... assembles Passive House buildings, and Richard Pedranti Architect (RPA), a full-service ... from the strategic partner’s Solsken Line of Model Homes . Independently, Ecocor ...
(Date:9/22/2017)... ... 22, 2017 , ... Tiny Transitions ( tinytransitions.com ), an ... and online newborn sleep consultations . , “We are seeing now, more ... owner Courtney Zentz, a pediatric sleep professional, post-partum doula and certified lactation counselor. ...
(Date:9/22/2017)... ... September 22, 2017 , ... Happy Living’s mission - to improve ... carries it into the entertaining and delicious worlds of theatre and wines. , ... Living) convinced him to turn his play into a book. The Greener The Grass ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with ... an obligatory tithe, and the freedom experienced when breaking free from this misconception. ... author, Lysa M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: